“Our Future is Light” Campaign Kicks off 2022 International Day of Light
An action-packed video styled as a blockbuster-movie trailer provides the linchpin for this year’s International Day of Light (IDL) campaign, “Our future is light. Play your part.” Released today, Day of Light features diverse characters successfully solving global-level problems using photonics-enabled technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005150/en/
Sponsored by SPIE, Optica, and IEEE Photonics Society, this year’s International Day of Light celebration showcases exciting, critical career opportunities in optics and photonics. (Graphic: Business Wire)
Three professional societies – SPIE, the international society for optics and photonics, IEEE Photonics Society, and Optica, Advancing Optics & Photonics Worldwide – partnered to create the video and the accompanying 2022 IDL campaign. “Our future is light. Play your part” promotes the importance of light-based technologies and interesting careers in optics and photonics, while raising awareness of the annual IDL celebration on 16 May. From technologies that improve vision and power smartphones to those that provide tools to study Earth and Space, from healthcare to communications at the speed of light, photonics is the key enabling technology of a brighter future.
The video, its look and feel inspired by the 2010 science-fiction thriller Inception, features Dawn, an optical-engineer action hero, who is busy saving the world with light-based technologies such as prisms, solar panels, spectral imaging, lasers, and lidar. The video also issues a lively invitation to real-life future scientists, technicians, engineers, and industry leaders: consider a career in photonics.
In conjunction with the video’s release, the related website includes an overview of the technologies mentioned in the film; depictions of professionals working in the field of optics and photonics, from optical engineers and laser technicians to academic researchers; and a selection of downloadable resources for education and careers.
“Many of the devices we use every day are comprised of light-based technologies made possible by the optics and photonics community,” said Optica CEO Elizabeth Rogan. “On the International Day of Light, we celebrate these contributions from our community and hope this celebration inspires others – particularly students – to study and work in light science and technology.”
“The International Day of Light is the perfect time to highlight the many varied and exciting career opportunities in optics and photonics,” noted SPIE CEO Kent Rochford. “Light-based technologies are providing much-needed solutions to some of our biggest global challenges and will continue to do so. This is a terrific time to be considering a career in the industry and we hope this year’s IDL campaign will reach and inspire future scientists, engineers, and technicians.”
"Each International Day of Light, we celebrate the long and rich history of optics and photonics that has brought so much to our everyday lives," said IEEE Photonics Society Executive Director Doug Razzano. "By continuing to advance light science and make known to the world the importance of the technologies derived from it, we will help to grow and support this vibrant technical community."
About the International Day of Light
The International Day of Light (IDL), celebrated annually on 16 May, is a global initiative highlighting the central role that light and light-based technologies play across science, culture, education, and sustainable development, in areas as diverse as medicine, communications, and energy. The 16 May date honors the anniversary of the first successful demonstration of a laser by physicist and engineer Theodore Maiman in 1960; the broad theme of light allows many different sectors of society worldwide to participate in activities that demonstrate how science, technology, and art, can help achieve the goals of UNESCO – education, equality, and peace. lightday.org.
About IEEE Photonics Society
The IEEE Photonics Society is the professional home for a global network of scientists, engineers and allied professionals who represent the laser, optoelectronics, and photonics community. As a Technical Society of the IEEE, the world’s largest technical professional organization dedicated to advancing technology for the benefit of humanity, the IEEE Photonics Society inspires community through highly cited publications, conferences, technology standards, and professional and educational activities. www.photonicssociety.org.
About Optica
Optica (formerly OSA), Advancing Optics and Photonics Worldwide, is the society dedicated to promoting the generation, application, archiving and dissemination of knowledge in the field. Founded in 1916, it is the leading organization for scientists, engineers, business professionals, students and others interested in the science of light. Optica’s renowned publications, meetings, online resources and in-person activities fuel discoveries, shape real-life applications and accelerate scientific, technical and educational achievement. Learn more at optica.org.
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $22 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005150/en/
Contact information
Daneet Steffens
Public Relations Manager
daneets@spie.org
+1 360 685 5478
@SPIEtweets
Ashley Collier
Corporate Communications Manager
ACollier@optica.org
+1 202 416 1419
@OpticaWorldwide
Kristen Mahan
Marketing Manager
k.mahan@ieee.org
+1 732 562 6694
@IEEEPhotonics
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom